The impressive results of the Aethlon (AEMD) Hemopurifier vaccine are predicted to drive the stock up by 247% from $2.21 to nearly $8. Considering the previous year, the company had the maximum mark of stock of $2.76 on February 8. The predicted $8 mark is the company’s best headline in a year, but what is the cause for it, and how long will it last?
Last week, Aethlon Medical announced that Aethlon Hemopurifier gave positive results in the treatment of two patients who were in critical condition with COVID-19.1; none of the patients was expected to survive. Therefore, the blood purifier was used by the FDA’s Emergency Use Authorization (EUA). In other words, doctors were forced to utilize a medication that had not yet been completely approved by the FDA because they had no other choice.
This lawsuit assisted the corporation in demonstrating its effectiveness against COVID-19, which led to a resonance in the society of investors and shareholders. One news about the successful use excited the market, what will happen when the drug is distributed? Investors should clearly understand that the company has a high potential in the production of anti-covid drugs, which has high demand today.